PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Gauges a company's financial stability and solvency. Value investors pay close attention to leverage and liquidity risk, ensuring the company has enough cushion to withstand downturns without impairing shareholder value.
0.12
D/E ratio under 0.3 - Rock-solid balance sheet territory. Warren Buffett would approve, but check if ROE is being sacrificed. Consider examining Interest Coverage to confirm debt serviceability.
0.76
Net debt under 1x EBITDA - Very conservative position that Benjamin Graham would endorse. Consider examining Interest Coverage to confirm strong debt service capacity.
-7.24
Negative coverage (negative EBIT) is a classic Benjamin Graham red flag. While possibly indicating turnaround potential, verify Current Ratio and Net Debt to EBITDA for overall financial health.
1.25
Current ratio 1.2-1.5 - Adequate liquidity that Peter Lynch might accept. Cross-check Interest Coverage to ensure overall financial health.
No Data
No Data available this quarter, please select a different quarter.